PHILADELPHIA, June 21,
2023 /PRNewswire/ -- Attorneys for Dr.
Raza Bokhari, the former CEO and
Executive Chairman of FSD Pharma (CSE: HUGE, NASDAQ: HUGE) have
filed two new claims against his former employer.
The two matters filed with the Ontario Superior Court of Justice
seek damages from FSD Pharma alleging breach of his employment
contract and for tortious and intentional interference with
economic relations during and subsequent to Bokhari's tenure as
FSD's Executive Chairman and CEO. The filings further claim
negligence, misrepresentation and other causes on the part of FSD's
founders, Anthony Durkacz and
Zeeshan Saeed before, during and
after the proxy fight that ultimately led to his constructive
dismissal in 2021. This proxy fight originated when Dr. Bokhari
opposed Durkacz and Saeed's demands to acquire Lucid
Psycheceuticals Inc, a shell company without any clinical stage
products in which Durkacz had a significant financial interest,
which he initially did not fully disclose.
Dr. Bokhari already has an existing Application before the
Ontario Superior Court of Justice, seeking to set aside the
Arbitral Award issued by Arbitrator J. Douglas Cunningham in November 2022. Dr. Bokhari, amongst other things,
asserts that (a) neither the Honorable Justice Cunningham, the
arbitrator overseeing his wrongful dismissal matter, nor
FSD Pharma's attorneys – Blake, Cassels & Graydon LLP
("Blakes"), disclosed past and ongoing business relationship
between themselves. This non-disclosure, if true, appears to be a
material violation of section 11 of the Ontario Arbitration Act of
1991, giving rise to a reasonable apprehension of bias against Dr.
Bokhari.
"Blake's makes a claim on their website that they are 'adept at
selecting the right arbitrators'", said Dr. Bokhari.
In addition to these disputes outlined above, FSD Pharma was
recently sued for $53,047,000 by GBB
Drink Lab in United States
District Court, District of Florida, for misappropriating trade secrets
and breaching non-disclosure agreements. The claim relates
to alleged actions engaged in by Saeed, Durkacz
and others at FSD Pharma after Dr. Bokhari's departure from the
company.
About Dr. Raza Bokhari
A recipient of Philadelphia Business Journal's "40 under 40"
award, Dr. Raza Bokhari, has
developed outstanding expertise in aggregating and accelerating
life sciences, healthcare services and Pharmaceutical R&D
companies.
Dr. Bokhari is the managing partner of RBx Capital, LP, and is
nominated as the Executive Chairman & CEO of Medicus Pharma,
Ltd, a biotech company developing innovative and non-invasive
therapies to treat cancerous melanomas. The company is expected to
begin trading on Toronto Stock Exchange (TSXV).
For more information on Dr. Bokhari, including the complete
story of his tenure at FSD Pharma, please visit
razabokhari.com
For Further Information:
RBx Capital, LP: Carolyn Bonner,
Principal (610)636-0184 cbonner@rbxcapital.net
View original
content:https://www.prnewswire.com/news-releases/dr-raza-bokhari-former-executive-chairman-and-ceo-of-fsd-pharma-files-two-additional-claims-against-the-company-seeking-relief-and-monetary-damages-exceeding-30-2-million-301856193.html
SOURCE RBx Capital LP